John A. Belperio
Pulmonary Disease · The Regents of the University of California
Credentials: · · · · ·
History
Research
Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis
Journal of Clinical Investigation · 2004 · 835 citations
CXC chemokines in angiogenesis
Review · Journal of Leukocyte Biology · 2000 · First of 7 authors · 611 citations
Senescence of Alveolar Type 2 Cells Drives Progressive Pulmonary Fibrosis
American Journal of Respiratory and Critical Care Medicine · 2021 · 431 citations
90 papers · 5 as a fellow
- RS
63 papers
62 papers
- MK
59 papers
51 papers
40 papers
37 papers · 12 as a fellow
37 papers
Grants
- 2003–2030
The UCLA Pulmonary and Critical Care Medicine Scientist Training Program (PCCM-STP)
National Heart, Lung, and Blood Institute · T32
Contact PI · $807.6K · University of California Los Angeles
- 2021–2028
Lung Transplant Clinical Trial Network (LT-CTN)
National Institute of Allergy and Infectious Diseases · U01
PI · $17.8M · Duke University
- 2021–2026
Validation of an in vitro Model of Progressive Fibrosis That Mimics Idiopathic Pulmonary Fibrosis
National Heart, Lung, and Blood Institute · U01
PI · $2.4M · University of California Los Angeles
- 2012–2024
Epithelial-Mesenchymal Interactions in Pulmonary Fibrosis and Chronic Allograft Dysfunction (CLAD)
National Heart, Lung, and Blood Institute · P01
Project lead · $2.3M · Cedars-Sinai Medical Center
Clinical trials
- 2026–2028
Principal investigator · Not yet recruiting · Phase 2
University of California, San Francisco
- 2013–2017
Principal investigator · Completed · Phase 2
Kyntra Bio
- 2009–2014
Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
Principal investigator · Completed · Phase 3
Duke University
- 2015–2019
CLAD Phenotype Specific Risk Factors and Mechanisms
Study chair · Completed
National Institute of Allergy and Infectious Diseases (NIAID)